R9Z.F ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Healthcare Biotechnology Frankfurt Exchange
0.3141 EUR
Close of Nov 12, 2026
0.2800 0.7400
Market cap
EUR 131M
P/E
-
P/B
1.44x
ROE
-27.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is R9Z.F undervalued?

Graham number

The Graham number of ImmuneOnco Biopharmaceuticals (Shanghai) Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

ImmuneOnco Biopharmaceuticals (Shanghai) Inc. fundamental analysis

No fundamental analysis for ImmuneOnco Biopharmaceuticals (Shanghai) Inc. yet.

ImmuneOnco Biopharmaceuticals (Shanghai) Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

ImmuneOnco Biopharmaceuticals (Shanghai) Inc., a biotechnology company, engages in the research and development of immuno-oncology therapies in China and the United States. The company's core product candidate is IMM01, which is in Phase Ib/IIa clinical trial to evaluate the combination with bortezomib and dexamethasone for the treatment of multiple myeloma; Phase II clinical trial in combination with azacitidine for the first-line treatment of higher-risk myelodysplastic sy…

Full company profile